Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q1 2026 Earnings Call Transcript
Operator: Good morning, and thank you for standing by. Welcome to Madrigal Pharmaceuticals First Quarter 2026 Earnings Conference Call.
Madrigal Pharmaceuticals Inc. (MDGL)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Baker Bros. Advisors Julian Baker And Felix Baker | 2,141,701 | $1,121,116,222 | 6.44% | |
| 2. | VenBio Select Advisor Kurt Von Emster | 1,818,181 | $951,763,208 | +1% | 9.36% |
| 3. | Paulson & Co John Paulson | 1,392,188 | $728,768,652 | -19% | 23.42% |
| 4. | Citadel Investment Group Ken Griffin | 453,843 | $237,573,195 | +1156% | 0.04% |
| 5. | Polar Capital Brian Ashford-Russell And Tim Woolley | 289,310 | $151,445,106 | +8% | 0.54% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $392.24 | 9,362 | $3,672,178.03 | 1,947,968 | 2025-08-20 | Filing | |
| $392.24 | 862 | $338,113.38 | 202,813 | 2025-08-20 | Filing | |
| $389.89 | 2,506 | $977,058.83 | 1,938,606 | 2025-08-20 | Filing | |
| $389.89 | 231 | $90,064.08 | 201,951 | 2025-08-20 | Filing | |
| $389.00 | 366 | $142,374.00 | 1,936,100 | 2025-08-20 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $519.98 | 80 | $41,598.40 | 22,015 | 2026-05-22 | Filing | |
| $518.76 | 782 | $405,668.76 | 22,095 | 2026-05-22 | Filing | |
| $517.59 | 1,497 | $774,835.37 | 22,877 | 2026-05-22 | Filing | |
| $516.87 | 723 | $373,693.97 | 24,374 | 2026-05-22 | Filing | |
| $515.92 | 657 | $338,960.69 | 25,097 | 2026-05-22 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,018,647 | $1,051,727,476 | 0.5% | |
| 2. | 1,993,687 | $1,043,635,334 | 10.38% | |
| 3. | 1,559,965 | $816,594,622 | 0.01% | |
| 4. | 841,145 | $440,314,173 | 0.02% | |
| 5. | 827,144 | $432,985,070 | 0.01% |
News See All
Madrigal Pharmaceuticals (MDGL) Surged on Strong Sales of Its Rezdiffra Drug
Janus Henderson Investors, an investment management company, released its “Forty Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. U.S.
What Makes Madrigal Pharma (MDGL) One of the Shorted Biotech Stocks to Buy
On February 20, Bank of America Securities lowered the price target on Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) from $570 to $529, resulting in upside potential above 22%.
10 Most Shorted Biotech Stocks to Buy According to Hedge Funds
On February 5, J.P. Morgan shared its views on trends that are expected to define healthcare in 2026.
Madrigal Pharmaceuticals (MDGL) Reports Record 2025 Revenue Driven by Rezdiffra Success
Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is one of the stocks with explosive growth potential.
10 Stocks With Explosive Growth Potential
On February 26, Darren Sissons, partner and portfolio manager at Campbell, Lee & Ross Investment Management, appeared on BNN Bloomberg to share his outlook on Global and Technology Stocks.
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q4 2025 Earnings Call Transcript
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q4 2025 Earnings Call Transcript February 19, 2026Madrigal Pharmaceuticals, Inc. misses on earnings expectations.
H.C. Wainwright Keeps Buy on Madrigal Pharmaceuticals (MDGL) on Strong Rezdiffra Uptake and F2/F3 MASH Patient Data
Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is one of the high short interest stocks to buy right now. On November 21, H.C.
11 High Short Interest Stocks to Buy Right Now
On December 8, Bob Doll, Crossmark Global Investments CEO and CIO, joined CNBC’s ‘Squawk on the Street’ to discuss the latest market trends and his expectations for the Fed.
Madrigal Pharmaceuticals (MDGL) Surged Following the Strong Launch and Execution of New Drug
Meridian Funds, managed by ArrowMark Partners, released its “Meridian Growth Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Hedge Fund Resource Center